Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Study of QEQ278 in Advanced Solid Tumors
jRCT2031220585Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of QEQ278 in non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), renal cell carcinoma (RCC) and 1 more, sponsored by Novartis. Primary endpoints: Dose-limiting toxicities during dose escalation for single-agent QEQ278, Safety profile in dose escalation and 4 more. Started May 2023; status: completed.
02
Drugs
QEQ278
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)renal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031220585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220585.